Levels of caffeine and its metabolites among U.S. smokers and nonsmokers.
Data from National Health and Nutrition Examination Survey for the years 2009-2010 were used to estimate the levels of caffeine and 14 of its metabolite among U.S. smokers and nonsmokers after adjustments were made for other factors that affect observed caffeine levels. In this study, when adjusted for daily caffeine intake, adjusted levels (AGM) of caffeine and its metabolites were not found to be statistically significantly different between smokers and nonsmokers. AGMs for caffeine and all of its metabolites were found to be statistically significantly higher (p < 0.01) among females aged ≥ 12 years than males. For caffeine, 1,3-dimethylxanthine, and 1,7-dimethylxanthine, those aged ≥ 20 years had statistically significantly higher (p < 0.01) AGM than those aged 12-19 years but the reverse was true for 7-methylxanthine and 3,7-dimethylxanthine (p ≤ 0.02). The order of the AGMs by race/ethnicity was non-Hispanic whites > Hispanics > non-Hispanic blacks and most of the differences were statistically significant, at least between non-Hispanic whites and non-Hispanic blacks (p < 0.01). In general, there was a statistically significant positive association between the levels of caffeine and its metabolites and body mass index as well as daily caffeine intake. However, the levels of 7-methylxanthine were negatively associated with body mass index.